LM11A-31, C12 H25 N3 O2, Pentanamide, 2-amino-3-methyl-N–[2-(4-morpholinyl)ethyl]– WO 2010102212 TO LONGO FRANK, PUB 10.09.2010 THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL PATENT LINK http://patentscope.wipo.int/search/en/WO2010102212 Scientists have developed a pill which they claim could help paralyzed people walk again. The new drug allowed mice with no movement in their lower limbs to walk… Continue reading LM11A-31, New drug can help paralyzed people walk again
Tag: DRUGS
New Data for Jakafi® (Ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting
Ruxolitinib (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile, CAS number 941678-49-5 Incyte Corporation (Nasdaq: INCY) announced today that several analyses from clinical studies of Jakafi® (ruxolitinib) will be presented at the 2012 American Society of Hematology (ASH) Annual Meeting from Dec. 8 to 11 , 2012 at the Georgia World Congress Center in Atlanta. Jakafi, an oral Janus kinase (JAK) inhibitor,… Continue reading New Data for Jakafi® (Ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting
FDA accepts AVEO-Astellas tivozanib NDA filing for renal cell carcinoma, 29 nov 2012
1-{2-Chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methylisoxazol-3-yl)urea AV-951 Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor. It is undergoing clinical trial investigation for the treatment of renal cell carcinomas.[1] An oral quinoline urea derivative, tivozanib suppresses angiogenesis by being selectively inhibitory against vascular endothelial growth factor.[2] It was developed by AVEO Pharmaceuticals.[3] It is designed to inhibit all three VEGF receptors.[4] Phase III results on advanced renal cell carcinoma suggest a 30%… Continue reading FDA accepts AVEO-Astellas tivozanib NDA filing for renal cell carcinoma, 29 nov 2012
Substituted indole derivatives for the treatment of immunological disorders,WO 2012156936, Novartis AG, Protein kinase C theta inhibitor
TITLE-Substituted indole derivatives for the treatment of immunological disorders Protein kinase C theta inhibitor WO 2012156936, 22.11.2012, Novartis AG GENERAL STRUCTURE DESCRIBED IS Phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1 -yl]-4-(7-methyl-1 H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1 -ylmethyl] ester 1H-NMR (400 MHz, DMSO-d6): 12.10 (s, 1 H), 8.08 (d, 1 H), 7.65-7.61 (m, 2H), 7.44 (f, 1 H), 7.20 (s, 1 H), 7.06 (f, 1… Continue reading Substituted indole derivatives for the treatment of immunological disorders,WO 2012156936, Novartis AG, Protein kinase C theta inhibitor
WO 2012130821, BENZOIC ACID SALT OF OTAMIXABAN (SANOFI)
Otamixaban (INN) is a direct factor Xa inhibitor,[1] currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome. Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate Guertin KR, Choi YM (2007). “The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development”. Curr. Med. Chem. 14 (23): 2471–81.doi:10.2174/092986707782023659. PMID 17979700. Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate, (CAS number 193153-04-7) has the International Nonproprietary Name Otamixaban The present… Continue reading WO 2012130821, BENZOIC ACID SALT OF OTAMIXABAN (SANOFI)